Skip to main content

Myriad's Stock Edges Up After Split

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics were trading up 2 percent at $45.44 in mid-afternoon trade on the Nasdaq following the two-for-one split of its shares before the market opened today.

The Salt Lake City-based molecular diagnostics firm announced the split last month. Following the split, it has around 95 million shares outstanding.

The split will alter the number of shares distributed to current shareholders in Myriad Pharmaceuticals, the proposed spinoff of Myriad's drug development business, which is expected to take place in the second quarter. Myriad has initially intended to grant its shareholders a half share of Myriad Pharmaceuticals stock for each share of Myriad Genetics held. Now, the firm expects to issue one quarter of a share in the new entity.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.